Min Li-Weber
Overview
Explore the profile of Min Li-Weber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sieber-Frank J, Stark H, Kalteis S, Prigge E, Kohler R, Andresen C, et al.
Cancer Med
. 2021 Sep;
10(19):6807-6822.
PMID: 34546000
Rocaglates are natural compounds that have been extensively studied for their ability to inhibit translation initiation. Rocaglates represent promising drug candidates for tumor treatment due to their growth-inhibitory effects on...
2.
Durr C, Hanna B, Schulz A, Lucas F, Zucknick M, Benner A, et al.
Haematologica
. 2018 Jan;
103(4):688-697.
PMID: 29326123
Chronic lymphocytic leukemia is a malignancy of mature B cells that strongly depend on microenvironmental factors, and their deprivation has been identified as a promising treatment approach for this incurable...
3.
Wu Y, Giaisi M, Kohler R, Chen W, Krammer P, Li-Weber M
Cancer Lett
. 2016 Dec;
389:70-77.
PMID: 27998762
Multiple myeloma (MM) is an incurable malignancy by the presently known therapies. TRAIL is a promising anticancer agent that virtually not shows any toxicity to normal cells. We have recently...
4.
Becker M, Muller P, Bajorat J, Schroeder A, Giaisi M, Amin E, et al.
Oncotarget
. 2016 Jun;
7(32):51908-51921.
PMID: 27340868
Chemotherapy is one of the pillars of anti-cancer therapy. Although chemotherapeutics cause regression of the primary tumor, many chemotherapeutics are often shown to induce or accelerate metastasis formation. Moreover, metastatic...
5.
Witzens-Harig M, Giaisi M, Kohler R, Krammer P, Li-Weber M
Int J Cancer
. 2015 Aug;
138(2):507-14.
PMID: 26260669
Over-expression of Bcl-2, Bcl-xL and Bcl-w is frequently associated with cancer resistance to chemotherapy. Navitoclax (ABT-263), an orally bio-available small-molecule mimetic of the Bcl-2 homology domain 3, specifically inhibits Bcl-2,...
6.
Neumann J, Yang Y, Kohler R, Giaisi M, Witzens-Harig M, Liu D, et al.
Int J Cancer
. 2015 Jun;
137(11):2739-48.
PMID: 26061604
Natural compounds are an important source for drug development. With an increasing cancer rate worldwide there is an urgent quest for new anti-cancer drugs. In this study, we show that...
7.
Yang Y, Zhang Y, Liu D, Li-Weber M, Shao B, Lin W
Fitoterapia
. 2015 May;
103:277-82.
PMID: 25936771
Chemical examination of the barks of mangrove plant Ceriops tagal resulted in the isolation of six new dolabrane-type diterpenes with the trivial names of tagalenes A-F (1-6), together with 10...
8.
Li-Weber M
Int J Cancer
. 2014 Jun;
137(8):1791-9.
PMID: 24895251
Rocaglamides (= flavaglines) are potent natural anti-cancer phytochemicals that inhibit cancer growth at nanomolar concentrations by the following mechanisms: (1) inhibition of translation initiation via inhibition of phosphorylation of the...
9.
Polier G, Giaisi M, Kohler R, Muller W, Lutz C, Buss E, et al.
Int J Cancer
. 2014 Jun;
136(3):688-98.
PMID: 24895203
Tumor initiation, progression and resistance to therapies are tightly associated with over-expression of anti-apoptotic proteins Bcl-2, Bcl-x(L), Bcl-w and Mcl-1. ABT-263 (Navitoclax), an orally bio-available small-molecule mimetic of the Bcl-2...
10.
Neumann J, Boerries M, Kohler R, Giaisi M, Krammer P, Busch H, et al.
Int J Cancer
. 2013 Oct;
134(8):1991-2002.
PMID: 24150948
Targeting the cancer cell cycle machinery is an important strategy for cancer treatment. Cdc25A is an essential regulator of cycle progression and checkpoint response. Over-expression of Cdc25A occurs often in...